Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

TIPRANKS01:30

Austin, Texas, United States, July 1st, 2026, FinanceWire Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648654021?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 01:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648654021","market":"us","top_or_hot":-1,"title":"Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals","media":"TIPRANKS","content":"<div>\n<p>Austin, Texas, United States, July 1st, 2026, FinanceWire Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) ...</p>\n\n<a href=\"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n","source":"tipranks_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy VERAXA Biotech (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-02 01:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral><strong>TIPRANKS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Austin, Texas, United States, July 1st, 2026, FinanceWire Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) ...</p>\n\n<a href=\"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"QQQ","symbol_name":"纳指100ETF","start_time":0,"source_url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral","article_id":"2648654021","we_media_id":null,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/why-veraxa-biotech-nasdaq-vrxa-shareholders-should-pay-serious-attention-to-antibody-therapeutics-sector-deals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2648654021","pubTimestamp":1782927021,"columns":[],"sourceInfo":{"source_id":"tipranks_highlight","name":"Tipranks"},"weMediaInfo":null,"summary":"Austin, Texas, United States, July 1st, 2026, FinanceWire Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) ...","collect":0,"end_time":0,"defaultTopTitle":"tipranks.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"QQQ":"纳指100ETF","BK4585":"ETF&股票定投概念","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","BK4139":"生物科技","IYW":"美国科技ETF-iShares","QID":"两倍做空纳斯达克指数ETF-ProShares","ONEQ":"Fidelity NASDAQ Composite Index ETF","LENZ":"Therapeutics","FTEC":"Fidelity MSCI Information Techno","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","TECS":"Direxion Daily Technology Bear 3X Shares","VRXA":"Veraxa Biotech Holding AG","PSQ":"做空纳斯达克100指数ETF-ProShares","NDX":"纳斯达克100指数","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","TQQQ":"纳指三倍做多ETF","QYLG":"Nasdaq 100 Covered Call & Growth ETF","TQQY":"GraniteShares YieldBOOST QQQ ETF","BK4588":"碎股","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","XBI":"SPDR S&P Biotech ETF","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","BK4007":"制药","QQQM":"NASDAQ100指数ETF-Invesco","BK4539":"次新股",".IXIC":"NASDAQ Composite","QLD":"2倍做多纳斯达克100指数ETF-ProShares","SQQQ":"纳指三倍做空ETF","BK4581":"高盛持仓","NVIW.SI":"NVDA 3xLongSG261006"},"translate_title":"为什么VERAXA Biotech（纳斯达克股票代码：VRXA）股东应认真关注抗体治疗行业交易","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/989b99c4f647612dec2b0efae7e614fb","symbols_score_info":{"QQQY":0.6,"QID":0.6,"NVIW.SI":0.6,".IXIC":1.5,"JEPQ":0.6,"MNQmain":0.6,"QYLG":0.6,"TQQY":0.6,"QQQM":0.6,"TECS":0.6,"XBI":1.5,"SQQQ":0.6,"QLD":0.6,"IYW":0.6,"VRXA":1.5,"ONEQ":0.6,"QQQJ":0.6,"FTEC":0.6,"NDX":0.6,"GPIQ":0.6,"TQQQ":0.6,"QDTE":0.6,"LENZ":1.5,"QQQA":0.6,"QQQE":0.6,"NQmain":0.6,"QQQ":0.6,"PSQ":0.6},"content_text":"Austin, Texas, United States, July 1st, 2026, FinanceWire Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) ...","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648654021","isCrawlerRequest":true}